Literature DB >> 11699800

Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.

R S James1, W S Sharp, T M Bastain, P P Lee, J M Walter, M Czarnolewski, F X Castellanos.   

Abstract

OBJECTIVE: To compare the efficacy and time course of single morning doses of Adderall, extended-release, and immediate-release dextroamphetamine sulfate.
METHOD: Thirty-five children with attention-deficit/hyperactivity disorder, combined type, were given Adderall, immediate-release dextroamphetamine, dextroamphetamine Spansules, and placebo in a randomized, double-blind, crossover study. Behavior ratings, locomotor activity measurements, and academic measures were obtained over a period of 8 weeks.
RESULTS: All three drugs exhibited robust efficacy versus placebo on nearly all measures. The effects of dextroamphetamine Spansules were less robust in the morning, particularly compared with Adderall, but they lasted 3 to 6 hours longer, depending on the measure. Although parent behavior ratings and locomotor activity showed improvements up to 12 hours after single doses of all three drugs, the number of math problems attempted and completed correctly 4 hours after dosing were only robustly increased by Spansules.
CONCLUSIONS: Both immediate-release amphetamines demonstrated earlier onset of effects, but dextroamphetamine Spansules showed more sustained effects that were present on a wider range of measures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699800     DOI: 10.1097/00004583-200111000-00006

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  22 in total

1.  Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core.

Authors:  Paul E A Glaser; Theresa C Thomas; B Matthew Joyce; F Xavier Castellanos; Greg A Gerhardt
Journal:  Psychopharmacology (Berl)       Date:  2004-09-30       Impact factor: 4.530

Review 2.  Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.

Authors:  Sarah C O S Padilha; Suzane Virtuoso; Fernanda S Tonin; Helena H L Borba; Roberto Pontarolo
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-19       Impact factor: 4.785

3.  Attention deficit/hyperactivity disorder: pharmacotherapy.

Authors:  Josephine Elia
Journal:  Psychiatry (Edgmont)       Date:  2005-01

Review 4.  ADHD in children and adolescents.

Authors:  Daphne Keen; Irene Hadijikoumi
Journal:  BMJ Clin Evid       Date:  2011-02-04

5.  Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers.

Authors:  B Matthew Joyce; Paul E A Glaser; Greg A Gerhardt
Journal:  Psychopharmacology (Berl)       Date:  2006-10-10       Impact factor: 4.530

Review 6.  New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

Authors:  Daniel F Connor; Ronald J Steingard
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  ADHD in children and adolescents.

Authors:  Daphne Keen; Irene Hadijikoumi
Journal:  BMJ Clin Evid       Date:  2008-10-02

Review 8.  Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?

Authors:  Raman Baweja; Richard E Mattison; James G Waxmonsky
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

9.  Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Jennifer L Donovan; Yan Jiang; Bryan B Gibson; C Lindsay DeVane; John S Markowitz
Journal:  Eur J Pharmacol       Date:  2007-10-05       Impact factor: 4.432

Review 10.  Psychostimulants and cognition: a continuum of behavioral and cognitive activation.

Authors:  Suzanne Wood; Jennifer R Sage; Tristan Shuman; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2013-12-16       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.